Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 13/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.53 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL274702 | 0.84 | LMNA (0.52) | EPAS1KMT2ACYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL5321373 | 0.83 | LMNA (0.61) | HTR2ASLC6A4KCNH2KMT2ACYP3A4 | |
| SCHEMBL2881823 | 0.82 | HTR2A (0.53) | HTR2ASLC6A4KCNH2EPAS1ALDH1A1 | |
| SCHEMBL18570625 | 0.81 | SCN8A (0.50) | SLC6A4EPAS1CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL5837555 | 0.81 | HTR2A (0.56) | HTR2ASLC6A4KCNH2EPAS1KMT2A | |
| SCHEMBL19563651 | 0.80 | LMNA (0.43) | HTR2ASLC6A4KCNH2EPAS1KMT2A | |
| SCHEMBL6151744 | 0.78 | KMT2A (0.46) | HTR2ASLC6A4KCNH2EPAS1KMT2A | |
| SCHEMBL5837334 | 0.78 | HTR2A (0.57) | HTR2ASLC6A4KCNH2KMO | |
| SCHEMBL275895 | 0.78 | ALDH1A1 (0.66) | KMT2ACYP2C19ALDH1A1CYP1A2MAPT | |
| SCHEMBL12437574 | 0.78 | KMT2A (0.46) | EPAS1KMT2ACYP3A4CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221151-A1 | 3-AMINO-2-PHENYLPYRROLIDINE DERIVATIVES | HUMPHREY JOHN MICHAEL | 2008-09-11 | — | — | US | disclosed |
| US-7381741-B2 | In which the amino is substituted by arylmethyl- or heteroarylmethyl- group, e.g., 2-Methoxybenzyl)-(2-phenylpyrrolidin-3-yl)-amine and 5-{[2-(3-Chloro-phenyl)-pyrrolidin-3-ylamino]-methyl}-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphalen-2-one; neurokinin 1 (Substance P) inhititors | PFIZER INC (US) | 2008-06-03 | — | — | US | disclosed |
| EP-1753718-A1 | 3-AMINO-2-PHENYLPYRROLIDINE DERIVATIVES | Pfizer Products Incorporated (US) | 2007-02-21 | — | — | EP | disclosed |
| US-7084165-B2 | Monoamine reuptake inhibitors for treatment of CNS disorders | PFIZER INC (US) | 2006-08-01 | — | — | US | disclosed |
| US-20050288358-A1 | 3-amino-2-phenylpyrrolidine derivatives | PFIZER INC. | 2005-12-29 | — | — | US | disclosed |
| WO-2005115976-A1 | 3-AMINO-2-PHENYLPYRROLIDINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20040048856-A1 | Monoamine reuptake inhibitors for treatment of CNS disorders | PFIZER INC | 2004-03-11 | — | — | US | disclosed |
| US-6677378-B2 | AS SEROTONIN, NOREPINEPHRINE AND DOPAMINE REUPTAKE INHIBITORS, FOR THERAPY OF CENTRAL NERVOUS SYSTEM AND OTHER DISORDERS | PFIZER INC. | 2004-01-13 | — | — | US | disclosed |
| US-20020143003-A1 | Monoamine reuptake inhibitors for treatment of CNS disorders | PFIZER INC. | 2002-10-03 | — | — | US | disclosed |
| EP-1154984-A1 | INHIBITORS FOR UPTAKE OF SEROTONINE, DOPAMINE OR NOREPINEPHRINE | Pfizer Products Inc. (US) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000050380-A1 | MONOAMINE REUPTAKE INHIBITORS FOR TREATMENT OF CNS DISORDERS | PFIZER PRODUCTS INC. (US) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221151-A1 | 3-AMINO-2-PHENYLPYRROLIDINE DERIVATIVES | PBK, KCND3, KCND2 | HTR2A 1153/4885SLC6A4 895/4885KCNH2 18/4885 |
| US-20050288358-A1 | 3-amino-2-phenylpyrrolidine derivatives | PBK, KCND3, KCND2 | HTR2A 1153/4885SLC6A4 895/4885KCNH2 18/4885 |
| US-20020143003-A1 | Monoamine reuptake inhibitors for treatment of CNS disorders | SLC6A2, SLC6A4, SLC6A3 | HTR2A 24/4885SLC6A4 2/4885KCNH2 1224/4885 |
| US-20040048856-A1 | Monoamine reuptake inhibitors for treatment of CNS disorders | SLC6A2, SLC6A3, SLC18A2 | HTR2A 14/4885SLC6A4 4/4885KCNH2 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.